NCT05697575Recruiting
Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice
Non-interventional Observational Study to Evaluate the Efficacy and Safety of Non-immune Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 336 (estimated)
- First submitted
- 14 Jan 2023
- Start date
- 1 Feb 2023
- Primary completion date
- 1 Feb 2030
- Lead sponsor
- National Society for Neurosonology and Cerebral Circulation
- Diseases
- Stroke
- NCT number
- NCT05697575
What you commit to
- Study type: Observational
- Planned participants: 336
- From 1 Feb 2023 to the primary completion date, 1 Feb 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase;
- The presence of a contraindication to thrombolytic therapy of ischemic stroke;
Other
- Pregnancy or lactation.
Who the study is looking for
- Age 18-85 ;
- Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;
- Thrombolytic therapy with the drug "non-immunogenic staphylokinase" is planned or has already been performed.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| St. Petersburg Research Institute of Emergency Medicine named after I.I. Janelidze Coordinator of this site? Confirm its status | Saint Petersburg | Russia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.